

Cohorts

All solid tumors



- RCC (n=36)
- Melanoma (n=9)
- NSCLC (n=7)
- Bladder (n=1)
- Prostate (n=1)
- Ovarian (n=1)
- Fallopian tube (n=1)
- Cellular uterine leiomyoma (n=1)
- Adenoma of unknown primary (n=1)

Samples



Pre-Post
treatment
Serum/Plasma



Pre-Post
treatment
Whole blood



Pre-Post
treatment
tumor biopsy

Pharmacokinetic and Pharmacodynamic assessment

- MEDI0680 serum concentration (n=57)
- Anti-drug antibodies (n=54)

- Circulating cytokines/chemokines (n=47)

- PD-1 receptor occupancy (n=40)
- T cell proliferation profile (n=41)

- PD-L1 IHC at baseline (n=22)
- CD8 IHC (n=14)
- Gene expression (n=11)

Endpoints

Secondary

Exploratory